Sintilimab trials for Colorectal cancer

All Sintilimab trials · All Colorectal cancer trials

Phase breakdown

Recruiting trials studying Sintilimab for Colorectal cancer

• A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer
  NCT07506109 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
  NCT06497985 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis
  NCT05057052 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instability-high, Locally Advanced Colorectal Cancer
  NCT06698757 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer
  NCT05450029 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer
  NCT06204094 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer
  NCT05236972 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer
  NCT06841159 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC
  NCT07474103 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer
  NCT06685276 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A Prospective, Randomized, Controlled Phase II Clinical Trial
  NCT07594925 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer
  NCT04636008 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell Carcinoma
  NCT07692152 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours
  NCT05427487 · Phase: Phase 1 · Ages: 18 Years to 85 Years · Sex: All (male and female) · 3 locations
• Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma
  NCT07468630 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location

Common questions

How many trials study Sintilimab for Colorectal cancer?

15 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.